ONXX
>>Second quarter Nexavar sales were 10% greater than first quarter.<<
Take away Japan (where Onyx only has single digit royalties), and sales were slightly DOWN in Euros.
However there was a large one-time clinical trial order in Q1. Take that out and ex-Japan sales in Euros were up ~3% from Q1 to Q2. Still sucks. But the present revenue run rate corresponds to only about a 4% worldwide market share in liver cancer (ignoring kidney and assuming $25K per patient taking Nexavar). Liver cancer is certainly ramping slower than I had expected, and no doubt the apparent effect is worsened due to their losing market share in kidney at the same time. But I've got to believe that 4% market share in liver cancer is not going to be the end of this story. There is only one approved systemic therapy, it has demonstrated clear improvement over SOC in 3 different randomized studies, and it is orally bioavailable.
A little more patience is in order ...
micro
Life is an IQ test.
email: microcapfun@yahoo.com
